Clinical trial
A Phase I Study of Imatinib Mesylate and SU011248 for Patients With Gastrointestinal Stromal Tumors
NCT00573404 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Imatinib Mesylate and SU011248 for Patients With Gastrointestinal Stromal Tumors
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- July 31, 2007
- Completion date
- March 31, 2011
- Enrollment
- 6 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
gastrointestinal stromal tumor